{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:38:27Z","timestamp":1789432707849,"version":"build-2803163510"},"reference-count":163,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T cells (CART) therapies have changed and continue to change the treatment paradigms for B\u2010cell malignancies because they can achieve durable complete remission in patients in whom multiple lines of treatment have failed. These unprecedented results have led to the widespread use of anti\u2010CD19 CART therapy for patients with relapsed and refractory aggressive large B\u2010cell lymphomas. While long\u2010term follow\u2010up data show that about one\u2010third of patients achieve prolonged complete remission and are potentially cured, the majority of patients either do not respond to CD19 CART therapy or eventually relapse after CD19 CART therapy. These results are, on the one hand, driving intense research into identifying mechanisms of relapse and, on the other hand, inspiring the development of novel strategies to overcome resistance. This review summarizes current clinical outcomes of CART immunotherapy in B\u2010cell non\u2010Hodgkin lymphomas, describes the most up\u2010to\u2010date understanding of mechanisms of relapse and discusses novel strategies to address resistance to CART therapy. We are indeed at the beginning of a scientific trek to explore the mechanisms of resistance, seek out new, more effective treatment approaches based on these discoveries and to boldly go where no other therapy has gone before!<\/jats:p>","DOI":"10.1111\/bjh.17191","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T04:55:05Z","timestamp":1606020905000},"page":"449-465","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["CAR\u2010T TREK through the lymphoma universe, to boldly go where no other therapy has gone before"],"prefix":"10.1111","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-3579","authenticated-orcid":false,"given":"Guido","family":"Ghilardi","sequence":"first","affiliation":[{"name":"Center for Cellular Immunotherapies Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Division of Hematology\u2010Oncology Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Braendstrup","sequence":"additional","affiliation":[{"name":"Department of Hematology Zealand University Hospital Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Division of Hematology\u2010Oncology Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Division of Hematology\u2010Oncology Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Division of Hematology\u2010Oncology Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Division of Hematology\u2010Oncology Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA"},{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.498"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25487"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00371"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12136"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0336-z"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127508"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.12.004"},{"key":"e_1_2_5_21_1","unstructured":"FDA.gov.TECARTUS (brexucabtagene autoleucel).2020."},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00090-z"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000377"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2743"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124750"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124177"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25951"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8008"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000307"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1527"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2973"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126081"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130983"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130983"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8040"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0620-8"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002395"},{"key":"e_1_2_5_49_1","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/1538-7445.AM2019-2320","article-title":"Abstract 2320: Avadomide (CC\u2010122) increases effector function and reverses exhaustion in chronically stimulated lisocabtagene maraleucel anti\u2010CD19 CAR T drug product","volume":"79","author":"Jessup HK","year":"2019","journal-title":"Can Res"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115769"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127751"},{"key":"e_1_2_5_52_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2217\/imt-2020-0022","article-title":"A Phase I clinical trial of chimeric antigen receptor\u2010modified T cells in patients with relapsed and refractory lymphoma","volume":"12","author":"Chen X","year":"2020","journal-title":"Immunotherapy"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126218"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0405"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131078"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0247-0"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8002"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8039"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8671"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-132057"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129015"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.3044"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_5_73_1","first-page":"1319","article-title":"Durable Remissions with Humanized CD19\u2010Targeted Chimeric Antigen Receptor (CAR)\u2010Modified T Cells in CAR\u2010Naive and CAR\u2010Exposed Children and Young Adults with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"130","author":"Maude SL","year":"2017","journal-title":"Blood"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0629-x"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3025"},{"key":"e_1_2_5_78_1","first-page":"578","article-title":"Long\u2010Term Follow\u2010up ZUMA\u20101: a pivotal trial of Axicabtagene Ciloleucel (Axi\u2010Cel; KTE\u2010C19) in patients with refractory aggressive Non\u2010Hodgkin Lymphoma (NHL)","volume":"130","author":"Neelapu SS","year":"2017","journal-title":"Blood"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00767"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738245"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119502"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115418"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130629"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011254"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"e_1_2_5_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0466"},{"key":"e_1_2_5_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0643-y"},{"key":"e_1_2_5_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0538"},{"key":"e_1_2_5_90_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566523218666181116093857"},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050602"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_5_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129"},{"key":"e_1_2_5_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"e_1_2_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004"},{"key":"e_1_2_5_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127490"},{"key":"e_1_2_5_98_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.125344"},{"key":"e_1_2_5_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6984"},{"key":"e_1_2_5_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117737"},{"key":"e_1_2_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009"},{"key":"e_1_2_5_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122954"},{"key":"e_1_2_5_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962"},{"key":"e_1_2_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.001"},{"key":"e_1_2_5_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833"},{"key":"e_1_2_5_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.012"},{"key":"e_1_2_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016"},{"key":"e_1_2_5_108_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070915"},{"key":"e_1_2_5_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000847"},{"key":"e_1_2_5_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131041"},{"key":"e_1_2_5_111_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2019-127683","article-title":"Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed\/Refractory (R\/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso\u2010cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response","volume":"134","author":"Reiss DJ","year":"2019","journal-title":"Blood"},{"key":"e_1_2_5_112_1","doi-asserted-by":"crossref","first-page":"CT153","DOI":"10.1158\/1538-7445.AM2019-CT153","article-title":"Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi\u2010Cel) in ZUMA\u20101","volume":"79","author":"Rossi JM","year":"2019","journal-title":"Cancer Res"},{"key":"e_1_2_5_113_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3028"},{"key":"e_1_2_5_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"e_1_2_5_115_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0850"},{"key":"e_1_2_5_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.003"},{"key":"e_1_2_5_117_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02453"},{"key":"e_1_2_5_118_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249559"},{"key":"e_1_2_5_119_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010038"},{"key":"e_1_2_5_120_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"key":"e_1_2_5_121_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26286"},{"key":"e_1_2_5_122_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1070"},{"key":"e_1_2_5_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.128_2629"},{"key":"e_1_2_5_124_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1300"},{"key":"e_1_2_5_125_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15218"},{"key":"e_1_2_5_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8"},{"key":"e_1_2_5_127_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0685-y"},{"key":"e_1_2_5_128_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15028"},{"key":"e_1_2_5_129_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365"},{"key":"e_1_2_5_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.4"},{"key":"e_1_2_5_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002"},{"key":"e_1_2_5_132_1","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446"},{"key":"e_1_2_5_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.006"},{"key":"e_1_2_5_134_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8"},{"key":"e_1_2_5_135_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00185"},{"key":"e_1_2_5_136_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.68_2630"},{"key":"e_1_2_5_137_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131499"},{"key":"e_1_2_5_138_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113979"},{"key":"e_1_2_5_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.065"},{"key":"e_1_2_5_140_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"e_1_2_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003"},{"key":"e_1_2_5_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"e_1_2_5_143_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"e_1_2_5_144_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183459"},{"key":"e_1_2_5_145_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"e_1_2_5_146_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320"},{"key":"e_1_2_5_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13562"},{"key":"e_1_2_5_148_1","article-title":"Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of epigenome","author":"Zhang Q","year":"2020","journal-title":"Blood"},{"key":"e_1_2_5_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.006"},{"key":"e_1_2_5_150_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0246-1"},{"key":"e_1_2_5_151_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"e_1_2_5_152_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0705-x"},{"key":"e_1_2_5_153_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8001"},{"key":"e_1_2_5_154_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129411"},{"key":"e_1_2_5_155_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2510"},{"key":"e_1_2_5_156_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127890"},{"issue":"14","key":"e_1_2_5_157_1","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR\u2010engineered T cells in refractory\/relapsed B cell lymphoma","volume":"136","author":"Tong C","year":"2020","journal-title":"Blood"},{"key":"e_1_2_5_158_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126429"},{"key":"e_1_2_5_159_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000017"},{"key":"e_1_2_5_160_1","doi-asserted-by":"publisher","DOI":"10.1097\/00129039-200106000-00001"},{"key":"e_1_2_5_161_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00729-7"},{"key":"e_1_2_5_162_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1337"},{"key":"e_1_2_5_163_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123742"},{"key":"e_1_2_5_164_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114152"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17191","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:10:29Z","timestamp":1693559429000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":163,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/bjh.17191"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17191","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"2020-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}